REG - Genflow Biosciences - First Day of Dealings

Genflow BiosciencesAnnouncement

17/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220117:nRSQ5588Ya&default-theme=true

RNS Number : 5588Y  Genflow Biosciences PLC  17 January 2022

NOT FOR PUBLICATION OR RELEASE IN OR INTO THE UNITED STATES OR AUSTRALIA,
CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH
AFRICA, OR ANY PROVINCE OR TERRITORY THEREOF OR TO OR FOR THE ACCOUNT OF ANY
NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES OR ANY PERSON RESIDENT IN
AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA.

 

17 January 2022

 

Genflow Biosciences Plc

("Genflow Biosciences" or "the Company")

 

First day of dealings

Admission to the Official List

 

Genflow Biosciences Plc ("Genflow" or "the Company"), a UK-based biotechnology
company focused on longevity and the development of therapies to counteract
the effects of aging and diseases associated with advanced age, is pleased to
announce that share dealings in its ordinary shares of £0.0003 each
("Ordinary Shares") will commence on the main market of the London Stock
Exchange from 8am today under the ticker symbol GENF.

The Company has been admitted to the standard segment of the Official List
following an oversubscribed placing of Ordinary Shares to raise £3.7 million
before expenses for the Company.

Genflow Biosciences is the first longevity biotechnology firm to list in
Europe and to join the London Stock Exchange.

A total of 47,036,500 Ordinary Shares (representing c16% of the Company's
issued share capital on Admission) were placed at 8 pence each, valuing
Genflow Biosciences at a market capitalisation of £23.4 million.

Clear Capital Markets Ltd is acting as the broker to the Company.

The purpose of the flotation is to raise the public profile and provide new
funds for the Company's expansion and long-term growth.

Dr. Eric Leire, Founder and CEO of Genflow Biosciences, said: "Genflow
Biosciences' debut on the London stock market is a major step in the Company's
development and provides a strong foundation to carry out our long-term growth
strategy. We are delighted with the strong support from a wide range of
investors, to develop life-changing gene therapies to target the ageing
process."

Company highlights

Genflow Biosciences was established in 2020 in order to develop therapies to
allow people to live longer, healthier lives.

 

Genflow has assembled a team of leading experts in the longevity and gene
delivery fields, with decades of experience in the biotechnology and
pharmaceutical sectors. The team benefits from a proven track record of value
creation and an important combination of technical gene therapy and
entrepreneurial skills.

 

The Company is led, and was founded, by Dr. Eric Leire, who has two decades of
experience in cell and gene therapy and has led several therapy companies,
including Enochian Biosciences which is listed on the Nasdaq. Dr Leire has
brought together experts in various fields within the longevity sector to
establish a strong Scientific Advisory Board which will guide Genflow's
pre-clinical and clinical programmes and provide external perspectives to
steer its research and development strategies.

 

Genflow's gene therapy approach represents a shift in the management of
age-related diseases as it is singularly focused on healthy longevity and the
development of a SIRT6 based therapy, as well as a holistic approach to the
nine hallmarks of ageing, while initially focusing on the first four
hallmarks. Longevity specialists typically look at just one hallmark, and
therefore can only hope to solve elements of the problem.

 

The Company is headquartered in London and has a Belgian R&D subsidiary
Genflow Biosciences, SRL ("Genflow BE"). Genflow BE's location enables it to
benefit from the relatively low operating costs and from substantial
(non-diluting) grants that support its research and development that are
available from Belgium's Wallonia region.

 

Genflow has the benefit of two patent applications in relation to: (i) a SIRT6
gene mutation found in centenarians (being those humans that live over 100
years ("Centenarians")) which the Directors believe has the potential to
enhance both health span and possibly life expectancy, pursuant to an
exclusive licence agreement entered into with the University of Rochester with
Genflow Biosciences SRL; and (ii) the method of administration and delivery of
the Company's product into humans and dogs.

 

Total Voting Rights

 

The total number of Ordinary Shares in the Company in issue immediately
following Admission will be 292,506,618 each with equal voting rights.

 

The total voting rights figure can be used by shareholders as the denominator
for the calculations by which they will determine whether they are required to
notify their interest in, or a change of their interest in, the Company under
the Disclosure, Guidance and Transparency Rules of the Financial Conduct
Authority.

 

The Company's Admission Document can also be found at https://genflowbio.com/
(https://genflowbio.com/) .

 

For further information please contact:

 

 Genflow Biosciences
 Dr Eric Leire                                             via Tancredi +44 203 434 2330

 Chief Executive

 Clear Capital Markets Ltd
 Corporate Broker

 Jonathan Critchley                                        +44 203 869 6086

 Keith Swann                                               +44 203 897 0981
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                                         +44 7957 549 906

 Helen Humphrey                                            +44 7449 226 720

 Benedetta Negri da Oleggio                                +44 7838 029 970

 genflowbio@tancredigroup.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  LISBFMLTMTTBBRT